964 related articles for article (PubMed ID: 30404863)
1. Enhanced detection of circulating tumor DNA by fragment size analysis.
Mouliere F; Chandrananda D; Piskorz AM; Moore EK; Morris J; Ahlborn LB; Mair R; Goranova T; Marass F; Heider K; Wan JCM; Supernat A; Hudecova I; Gounaris I; Ros S; Jimenez-Linan M; Garcia-Corbacho J; Patel K; Østrup O; Murphy S; Eldridge MD; Gale D; Stewart GD; Burge J; Cooper WN; van der Heijden MS; Massie CE; Watts C; Corrie P; Pacey S; Brindle KM; Baird RD; Mau-Sørensen M; Parkinson CA; Smith CG; Brenton JD; Rosenfeld N
Sci Transl Med; 2018 Nov; 10(466):. PubMed ID: 30404863
[TBL] [Abstract][Full Text] [Related]
2. Refined characterization of circulating tumor DNA through biological feature integration.
Markus H; Chandrananda D; Moore E; Mouliere F; Morris J; Brenton JD; Smith CG; Rosenfeld N
Sci Rep; 2022 Feb; 12(1):1928. PubMed ID: 35121756
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
4. Diverse fragment lengths dismiss size selection for serum cell-free DNA: a comparative study of serum and plasma samples.
Huang Y; Mu J; Qi L; Ge W; Fang X; Song Y; Yuan Y; Zheng S
Clin Chem Lab Med; 2020 Aug; 58(9):1451-1459. PubMed ID: 32229658
[TBL] [Abstract][Full Text] [Related]
5. Origin of circulating free DNA in patients with lung cancer.
Abe T; Nakashima C; Sato A; Harada Y; Sueoka E; Kimura S; Kawaguchi A; Sueoka-Aragane N
PLoS One; 2020; 15(7):e0235611. PubMed ID: 32634139
[TBL] [Abstract][Full Text] [Related]
6. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
7. Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
Ganesamoorthy D; Robertson AJ; Chen W; Hall MB; Cao MD; Ferguson K; Lakhani SR; Nones K; Simpson PT; Coin LJM
BMC Cancer; 2022 Jan; 22(1):85. PubMed ID: 35057759
[TBL] [Abstract][Full Text] [Related]
8. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
[TBL] [Abstract][Full Text] [Related]
10. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
11. Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors.
Lenaerts L; Vandenberghe P; Brison N; Che H; Neofytou M; Verheecke M; Leemans L; Maggen C; Dewaele B; Dehaspe L; Vanderschueren S; Dierickx D; Vandecaveye V; Amant F; Vermeesch JR
Ann Oncol; 2019 Jan; 30(1):85-95. PubMed ID: 30371735
[TBL] [Abstract][Full Text] [Related]
12. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
[No Abstract] [Full Text] [Related]
13. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction.
Lee JS; Kim M; Seong MW; Kim HS; Lee YK; Kang HJ
Clin Chem Lab Med; 2020 Mar; 58(4):527-532. PubMed ID: 31874093
[TBL] [Abstract][Full Text] [Related]
14. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
15. Detection of ctDNA from Dried Blood Spots after DNA Size Selection.
Heider K; Wan JCM; Hall J; Belic J; Boyle S; Hudecova I; Gale D; Cooper WN; Corrie PG; Brenton JD; Smith CG; Rosenfeld N
Clin Chem; 2020 May; 66(5):697-705. PubMed ID: 32268361
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
17. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
18. Increased detection of circulating tumor DNA by short fragment enrichment.
Liu Y; Liu Y; Wang Y; Li L; Yao W; Song Y; Liu B; Chen W; Santarpia M; Rossi E; Zamarchi R; Wang Z; Wang Q; Cheng G
Transl Lung Cancer Res; 2021 Mar; 10(3):1501-1511. PubMed ID: 33889525
[TBL] [Abstract][Full Text] [Related]
19. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients.
Park G; Park JK; Son DS; Shin SH; Kim YJ; Jeon HJ; Lee J; Park WY; Lee KH; Park D
Sci Rep; 2018 Aug; 8(1):11631. PubMed ID: 30072705
[TBL] [Abstract][Full Text] [Related]
20. Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.
Szymanski JJ; Sundby RT; Jones PA; Srihari D; Earland N; Harris PK; Feng W; Qaium F; Lei H; Roberts D; Landeau M; Bell J; Huang Y; Hoffman L; Spencer M; Spraker MB; Ding L; Widemann BC; Shern JF; Hirbe AC; Chaudhuri AA
PLoS Med; 2021 Aug; 18(8):e1003734. PubMed ID: 34464388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
